comparemela.com

Latest Breaking News On - National comprehensive cancer network - Page 7 : comparemela.com

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-states
Chicago
Illinois
American
Castle-bioscience
Castle-biosciences
Derek-maetzold
National-comprehensive-cancer-network
Nasdaq
Castle-biosciences-inc
Facebook
Linkedin

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy had 50% higher.

United-states
California
American
Saraht-arron
Castle-biosciences
Castle-biosciences-inc
Facebook
Nasdaq
Instagram
Linkedin
National-comprehensive-cancer-network
American-joint-committee-on-cancer-eighth-edition

NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management

NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Fort-myers
Florida
United-states
California
San-diego
Aliso-viejo
Chicago
Illinois
Cambridge
Cambridgeshire
United-kingdom
North-carolina

NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing

Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.

National-comprehensive-cancer-network
Optimizing-treatment-outcomes
Concurrent-biomarker-testing
Concurrent-biomarker

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.